{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:06:12Z","timestamp":1780567572945,"version":"3.54.1"},"reference-count":0,"publisher":"Neoplasia Research","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Anal. Oncol."],"abstract":"<jats:p>This study evaluated the antiproliferative effects of cisplatin, dihydroartemisinin, metformin and taro extract on MDA-MB-231 triple-negative breast cancer (TNBC) cell lines. Cisplatin at half maximal inhibitory concentration, IC50 (20 \u00b5M) induced ~45% cell death (p &lt; 0.001 vs control), while metformin (MET), dihydroartemisinin (DHA), and taro extract (TE) alone showed minimal cell death. Combination treatments (Cis + MET, Cis + DHA, and Cis + TE) significantly increased cytotoxicity to ~60% cell death on average (p &lt; 0.01 vs cisplatin alone), with Cis + TE producing the greatest effect (~90%). The triple metabolic combination without cisplatin caused less than10% cell death (p &lt; 0.001 vs cisplatin-containing groups), probably supporting a cisplatin-dependent cell death.<\/jats:p>","DOI":"10.30683\/1927-7229.2026.15.06","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:36:35Z","timestamp":1780565795000},"page":"53-57","source":"Crossref","is-referenced-by-count":0,"title":["Initial Evaluation of Dihydroartemisinin (DHA), Metformin and Taro Extract in Combination with Cisplatin for Enhanced Cytotoxicity in Triple-Negative Breast Cancer (TNBC) Cell Lines"],"prefix":"10.30683","volume":"15","author":[{"given":"Ada Morgan","family":"Godwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u2019Turie","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirendranath","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolapo","family":"Adedeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"12136","published-online":{"date-parts":[[2026,6,4]]},"container-title":["Journal of Analytical Oncology"],"original-title":[],"link":[{"URL":"https:\/\/neoplasiaresearch.com\/index.php\/jao\/article\/download\/956\/816","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/neoplasiaresearch.com\/index.php\/jao\/article\/download\/956\/816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:36:35Z","timestamp":1780565795000},"score":1,"resource":{"primary":{"URL":"https:\/\/neoplasiaresearch.com\/index.php\/jao\/article\/view\/956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":0,"URL":"https:\/\/doi.org\/10.30683\/1927-7229.2026.15.06","relation":{},"ISSN":["1927-7229"],"issn-type":[{"value":"1927-7229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}